Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Sulfasalazine vs placebo Mean improvement in Bath ankylosing spondylitis disease activity index (BASDAI) ‐ not reported · Patients with ankylosing spondylitis Sulfasalazine for ankylosing spondylitis (2014) · Cochrane | no estimate extracted | NR | No studies |
Sulfasalazine vs placebo Mean improvement in Bath ankylosing spondylitis function index (BASFI) ‐ not reported · Patients with ankylosing spondylitis Sulfasalazine for ankylosing spondylitis (2014) · Cochrane | no estimate extracted | NR | No studies |
Sulfasalazine vs placebo Mean improvement in Bath ankylosing spondylitis metrology index (BASMI) ‐ not reported · Patients with ankylosing spondylitis Sulfasalazine for ankylosing spondylitis (2014) · Cochrane | no estimate extracted | NR | No studies |
Sulfasalazine vs placebo Radiographic progress ‐ not reported · Patients with ankylosing spondylitis Sulfasalazine for ankylosing spondylitis (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT CANNABIS AND PSYCHOSIS) vs NON‐SPECIFIC PSYCOEDUCTION Global state: relapse ‐ medium term ‐ not reported · patients with SCHIZOPHRENIA AND CANNABIS USE Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT CANNABIS AND PSYCHOSIS) vs NON‐SPECIFIC PSYCOEDUCTION General functioning: no clinically important change in general functioning ‐ medium term ‐ not reported · patients with SCHIZOPHRENIA AND CANNABIS USE Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT CANNABIS AND PSYCHOSIS) vs NON‐SPECIFIC PSYCOEDUCTION Adverse effects: no clinically important adverse effects ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT CANNABIS AND PSYCHOSIS) vs NON‐SPECIFIC PSYCOEDUCTION Leaving the study early ‐ medium term ‐ not reported · patients with SCHIZOPHRENIA AND CANNABIS USE Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: PSYCHOLOGICAL THERAPY (SPECIFICALLY ABOUT CANNABIS AND PSYCHOSIS) vs NON‐SPECIFIC PSYCOEDUCTION Satisfaction with treatment ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' vs ANTIPSYCHOTIC 'B' for Global state: relapse ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA. Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' vs ANTIPSYCHOTIC 'B' for General functioning: no clinically important change in general functioning ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA. Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: ANTIPSYCHOTIC 'A' vs ANTIPSYCHOTIC 'B' for Satisfaction with treatment ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA. Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABINOID AS TREATMENT: CANNABIDIOL vs AMISULPRIDE Behaviour: Cannabis use: 1. frequency of use (group‐based therapy) (high = bad) ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABINOID AS TREATMENT: CANNABIDIOL vs AMISULPRIDE Mental state: PANSS total (high = bad) ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABINOID AS TREATMENT: CANNABIDIOL vs AMISULPRIDE Global state: relapse ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABINOID AS TREATMENT: CANNABIDIOL vs AMISULPRIDE General functioning: no clinically important change in general functioning ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABINOID AS TREATMENT: CANNABIDIOL vs AMISULPRIDE Adverse effects: measured adverse events ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABINOID AS TREATMENT: CANNABIDIOL vs AMISULPRIDE Leaving the study early: any reason ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABINOID AS TREATMENT: CANNABIDIOL vs AMISULPRIDE Satisfaction with treatment ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY vs TREATMENT Global state: relapse ‐ medium term ‐ not reported · patients with SCHIZOPHRENIA AND CANNABIS USE Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY vs TREATMENT Adverse effects: no clinically important adverse effects ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY vs TREATMENT Leaving the study early ‐ medium term ‐ not reported · patients with SCHIZOPHRENIA AND CANNABIS USE Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
CANNABIS REDUCTION: ADJUNCT PSYCHOLOGICAL THERAPY vs TREATMENT Satisfaction with treatment ‐ medium term ‐ not measured · patients with SCHIZOPHRENIA AND CANNABIS USE Cannabis and schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR CI: confidence interval. · adults with attention deficit hyperactivity disorder (ADHD) Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults (2014) · Cochrane | no estimate extracted | NR | No studies |
Diacerein vs placebo Quality of Life not measured · participants with osteoarthritis Diacerein for osteoarthritis (2014) · Cochrane | no estimate extracted | NR | No studies |
Diacerein vs placebo Total number of serious adverse events not measured · participants with osteoarthritis Diacerein for osteoarthritis (2014) · Cochrane | no estimate extracted | NR | No studies |
Interventions to reduce blood loss during myomectomy for fibroids vs placebo or no treatment Intervention · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | no estimate extracted | NR | No studies |
Bupivicaine plus epinephrine vs placebo to reduce blood loss during myomectomy Need for blood transfusion Participants who received blood transfusion · Women with fibroids Interventions to reduce haemorrhage during myomectomy for fibroids (2014) · Cochrane | no estimate extracted | NR | No studies |
ACUPUNCTURE added to LOW DOSE ANTIPSYCHOTICS vs STANDARD DOSE ANTIPSYCHOTICS Service outcomes: Hospitalisation · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ACUPUNCTURE added to LOW DOSE ANTIPSYCHOTICS vs STANDARD DOSE ANTIPSYCHOTICS Quality of life: No clinically important change in quality of life · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ACUPUNCTURE added to LOW DOSE ANTIPSYCHOTICS vs STANDARD DOSE ANTIPSYCHOTICS Economic outcomes: Cost of care · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ACUPUNCTURE vs STANDARD DOSE ANTIPSYCHOTICS Service outcomes: Hospitalisation · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ACUPUNCTURE vs STANDARD DOSE ANTIPSYCHOTICS Quality of life: No clinically important change in quality of life · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ACUPUNCTURE vs STANDARD DOSE ANTIPSYCHOTICS Economic outcomes: Cost of care · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ACUPUNCTURE added to TCM DRUG vs TCM DRUG Mental state: No clinically important change in mental state · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ACUPUNCTURE added to TCM DRUG vs TCM DRUG Service outcomes: Hospitalisation · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ACUPUNCTURE added to TCM DRUG vs TCM DRUG Quality of life: No clinically important change in quality of life · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ACUPUNCTURE added to TCM DRUG vs TCM DRUG Economic outcomes: Cost of care · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ACUPUNCTURE vs TCM DRUG Mental state: No clinically important change in general mental state · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ACUPUNCTURE vs TCM DRUG Service outcomes: Hospitalisation · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ACUPUNCTURE vs TCM DRUG Adverse effects: Clinically important general adverse effects · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ACUPUNCTURE vs TCM DRUG Quality of life: No clinically important change in quality of life · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ACUPUNCTURE vs TCM DRUG Economic outcomes: Cost of care · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ELECTRIC ACUPUNCTURE CONVULSIVE THERAPY vs ELECTROCONVULSIVE THERAPY Global state: Relapse · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ELECTRIC ACUPUNCTURE CONVULSIVE THERAPY vs ELECTROCONVULSIVE THERAPY Mental state: No clinically important change in general mental state · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ELECTRIC ACUPUNCTURE CONVULSIVE THERAPY vs ELECTROCONVULSIVE THERAPY Service outcomes: Hospitalisation · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ELECTRIC ACUPUNCTURE CONVULSIVE THERAPY vs ELECTROCONVULSIVE THERAPY Quality of life: No clinically important change in quality of life · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ELECTRIC ACUPUNCTURE CONVULSIVE THERAPY vs ELECTROCONVULSIVE THERAPY Economic outcomes: Cost of care · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ACUPUNCTURE added to STANDARD DOSE ANTIPSYCHOTICS vs STANDARD DOSE ANTIPSYCHOTICS Quality of life: No clinically important change in quality of life · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
ACUPUNCTURE added to STANDARD DOSE ANTIPSYCHOTICS vs STANDARD DOSE ANTIPSYCHOTICS Economic outcomes: Cost of care · patients with schizophrenia Acupuncture for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |